Latest news with #StoneCo
Yahoo
6 days ago
- Business
- Yahoo
Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates
As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff concerns and economic health. In such a climate, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for those looking to invest wisely amidst these complex conditions. Top 10 Undervalued Stocks Based On Cash Flows In The United States Name Current Price Fair Value (Est) Discount (Est) StoneCo (STNE) $13.50 $26.82 49.7% Similarweb (SMWB) $7.56 $14.88 49.2% Old National Bancorp (ONB) $20.47 $40.10 49% MNTN (MNTN) $24.98 $49.17 49.2% Ligand Pharmaceuticals (LGND) $146.32 $290.34 49.6% Kyndryl Holdings (KD) $30.18 $59.38 49.2% Fiverr International (FVRR) $22.91 $45.03 49.1% BioLife Solutions (BLFS) $20.64 $40.11 48.5% Berkshire Hills Bancorp (BHLB) $24.04 $46.58 48.4% Atlantic Union Bankshares (AUB) $31.39 $62.54 49.8% Click here to see the full list of 167 stocks from our Undervalued US Stocks Based On Cash Flows screener. We're going to check out a few of the best picks from our screener tool. Ligand Pharmaceuticals Overview: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses biopharmaceutical assets globally, with a market cap of approximately $2.75 billion. Operations: Ligand Pharmaceuticals generates revenue through the development and licensing of biopharmaceutical assets on a global scale. Estimated Discount To Fair Value: 49.6% Ligand Pharmaceuticals appears undervalued, trading at US$146.32, significantly below its estimated fair value of US$290.34. Recent financial results show a turnaround with Q2 net income of US$4.85 million from a previous loss, and raised 2025 revenue guidance to US$200-225 million. The company has also secured new revenue streams through royalties and milestone payments from ZELSUVMI's launch, enhancing cash flow prospects despite slower overall revenue growth compared to the broader market expectations. According our earnings growth report, there's an indication that Ligand Pharmaceuticals might be ready to expand. Take a closer look at Ligand Pharmaceuticals' balance sheet health here in our report. Global-E Online Overview: Global-E Online Ltd. operates a direct-to-consumer cross-border e-commerce platform across Israel, the United Kingdom, the United States, and other international markets, with a market cap of approximately $5.91 billion. Operations: The company generates revenue of $796.77 million from its Internet Information Providers segment. Estimated Discount To Fair Value: 27.9% Global-E Online is trading at US$35.17, notably below its estimated fair value of US$48.75, highlighting potential undervaluation based on cash flows. Recent strategic partnerships with DHL and Shopify enhance its market position and revenue prospects, with earnings projected to grow 63.45% annually and expected profitability within three years. Despite a low forecasted return on equity of 16.6%, the company's revenue growth rate surpasses both industry and market averages, reinforcing its attractive valuation profile amidst robust expansion plans. The growth report we've compiled suggests that Global-E Online's future prospects could be on the up. Click to explore a detailed breakdown of our findings in Global-E Online's balance sheet health report. Warner Music Group Overview: Warner Music Group Corp. is a music entertainment company operating in the United States, the United Kingdom, Germany, and internationally with a market cap of approximately $15.66 billion. Operations: Warner Music Group generates revenue through its Recorded Music and Music Publishing segments, with the former focusing on recorded music sales, streaming, licensing, and artist services while the latter involves licensing compositions for use in recordings, public performances, and related rights. Estimated Discount To Fair Value: 10.3% Warner Music Group trades at US$31.15, slightly below its estimated fair value of US$34.73, indicating potential undervaluation based on cash flows. Despite recent earnings showing a net loss of US$16 million for Q3 2025, the company maintains a robust growth forecast with earnings expected to rise by 21.53% annually over the next three years. Strategic initiatives like the joint venture with Bain Capital for music catalog acquisitions may bolster long-term cash flow prospects amidst high debt levels. Upon reviewing our latest growth report, Warner Music Group's projected financial performance appears quite optimistic. Get an in-depth perspective on Warner Music Group's balance sheet by reading our health report here. Seize The Opportunity Navigate through the entire inventory of 167 Undervalued US Stocks Based On Cash Flows here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LGND GLBE and WMG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
08-08-2025
- Business
- Yahoo
StoneCo Ltd. (STNE) Beats Q2 Earnings and Revenue Estimates
StoneCo Ltd. (STNE) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.3 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +8.33%. A quarter ago, it was expected that this company would post earnings of $0.32 per share when it actually produced earnings of $0.34, delivering a surprise of +6.25%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. StoneCo, which belongs to the Zacks Internet - Software industry, posted revenues of $672.06 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.91%. This compares to year-ago revenues of $615.13 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. StoneCo shares have added about 68.3% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for StoneCo? While StoneCo has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for StoneCo was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.36 on $661.83 million in revenues for the coming quarter and $1.49 on $2.65 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Cellebrite DI Ltd. (CLBT), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 14. This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Cellebrite DI Ltd.'s revenues are expected to be $112.44 million, up 17.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report StoneCo Ltd. (STNE) : Free Stock Analysis Report Cellebrite DI Ltd. (CLBT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-08-2025
- Business
- Yahoo
Inter & Co Leads 3 Stocks That May Be Trading Below Estimated Value
In a market where the S&P 500 is nearing record highs and the Nasdaq Composite continues to climb, investors are keenly observing shifts influenced by tariffs and economic outlooks. Amid this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to capitalize on market fluctuations. Top 10 Undervalued Stocks Based On Cash Flows In The United States Name Current Price Fair Value (Est) Discount (Est) StoneCo (STNE) $13.41 $26.38 49.2% Similarweb (SMWB) $7.57 $14.92 49.2% Rhythm Pharmaceuticals (RYTM) $90.01 $178.91 49.7% Old National Bancorp (ONB) $20.72 $40.13 48.4% Gogo (GOGO) $15.31 $30.29 49.5% First Commonwealth Financial (FCF) $16.54 $32.97 49.8% Duolingo (DUOL) $343.61 $677.05 49.2% Berkshire Hills Bancorp (BHLB) $24.23 $46.67 48.1% Atlantic Union Bankshares (AUB) $31.69 $62.54 49.3% ACNB (ACNB) $41.75 $80.99 48.5% Click here to see the full list of 176 stocks from our Undervalued US Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Inter & Co Overview: Inter & Co, Inc. operates through its subsidiaries in banking, spending, investments, insurance brokerage, and inter shop businesses across Brazil and the United States with a market cap of $2.98 billion. Operations: Inter & Co generates revenue through its operations in banking and spending, investments, insurance brokerage, and inter shop businesses across Brazil and the United States. Estimated Discount To Fair Value: 11.1% Inter & Co. reported strong financial performance with net interest income and net income rising significantly year-over-year for the first half of 2025. Despite trading slightly below its estimated fair value at $7.46 compared to $8.39, it faces challenges with a high level of bad loans at 9.3%. However, its earnings and revenue are expected to grow significantly above market averages, indicating potential long-term growth prospects amidst current undervaluation concerns based on cash flows. The analysis detailed in our Inter & Co growth report hints at robust future financial performance. Delve into the full analysis health report here for a deeper understanding of Inter & Co. Grindr Overview: Grindr Inc. operates a social networking and dating application catering to the LGBTQ community globally, with a market cap of approximately $3.49 billion. Operations: The company generates revenue primarily from its Internet Information Providers segment, totaling $363.23 million. Estimated Discount To Fair Value: 44.5% Grindr is trading at a significant discount, with its price below the estimated fair value of US$33.59, currently at US$18.64. Despite recent insider selling and slower projected revenue growth of 17% per year compared to its peers, the company is expected to achieve profitability within three years. The reaffirmed guidance for a 26% or greater revenue increase in 2025 supports its potential as an undervalued opportunity based on cash flows amidst executive transitions. Upon reviewing our latest growth report, Grindr's projected financial performance appears quite optimistic. Click here to discover the nuances of Grindr with our detailed financial health report. Wolverine World Wide Overview: Wolverine World Wide, Inc. is involved in designing, manufacturing, sourcing, marketing, licensing, and distributing footwear, apparel, and accessories across various regions including the United States and international markets with a market cap of $1.90 billion. Operations: Wolverine World Wide generates revenue through its diverse operations in footwear, apparel, and accessories across regions such as the United States, Europe, the Middle East, Africa, the Asia Pacific, Canada and Latin America. Estimated Discount To Fair Value: 29.8% Wolverine World Wide trades at a discount, with its current price of US$26.98 below the estimated fair value of US$38.41. Despite high debt levels, its recent profitability and forecasted earnings growth of 24.6% annually over three years highlight potential value based on cash flows. However, revenue growth is expected to lag behind the broader market at 5.7% per year, and recent uncertainty around tariffs has led to a withdrawal of full-year guidance for 2025. In light of our recent growth report, it seems possible that Wolverine World Wide's financial performance will exceed current levels. Click to explore a detailed breakdown of our findings in Wolverine World Wide's balance sheet health report. Make It Happen Delve into our full catalog of 176 Undervalued US Stocks Based On Cash Flows here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include INTR GRND and WWW. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-08-2025
- Business
- Yahoo
Zacks.com featured highlights StoneCo, CVS Health, KT, KB Financial and USANA Health Sciences
For Immediate Release Chicago, IL – August 6, 2025 – The stocks in this week's article are StoneCo STNE, CVS Health CVS, KT Corp. KT, KB Financial Group KB and USANA Health Sciences USNA. 5 Low Price-to-Book Stocks to Add to Your Portfolio in August While there are a host of valuation metrics, the first to cross one's mind is the price-to-earnings ratio. However, in the case of loss-making companies, the price-to-earnings (P/E) ratio is negative. In such a scenario, price-to-sales (P/S) could indicate the hidden strength of the business. The price-to-book ratio (P/B ratio) is also an easy-to-use tool for identifying low-priced stocks that have high-growth prospects. The P/B ratio is used to calculate how much an investor needs to pay for each dollar of the book value of a stock. It is calculated by dividing the current closing price of the stock by the latest quarter's book value per share. The P/B ratio helps identify low-priced stocks with high growth prospects. StoneCo, CVS Health, KT Corp., KB Financial Group and USANA Health Sciences are some such stocks. Now, let us understand the concept of book value. What Is Book Value? There are several ways by which book value can be defined. Book value is the total value that would be left over, according to the company's balance sheet, if it goes bankrupt immediately. In other words, this is what shareholders would theoretically receive if a company liquidates all its assets after paying off all its liabilities. It is calculated by subtracting total liabilities from the total assets of a company. In most cases, this equates to common stockholders' equity on the balance sheet. However, depending on the company's balance sheet, intangible assets should also be subtracted from the total assets to determine book value. Understanding P/B Ratio By comparing the book value of equity to its market price, we get an idea of whether a company is under- or overpriced. However, like P/E or P/S ratio, it is always better to compare P/B ratios within industries. A P/B ratio of less than one means that the stock is trading at less than its book value or the stock is undervalued and, therefore, a good buy. Conversely, a stock with a ratio greater than one can be interpreted as being overvalued or relatively expensive. For example, a stock with a P/B ratio of 2 means that we pay $2 for every $1 of book value. Thus, the higher the P/B, the more expensive the stock. But there is a warning. A P/B ratio of less than one can also mean that the company is earning weak or even negative returns on its assets or that the assets are overstated. In such a case, the stock should be shunned because it may be destroying shareholder value. Conversely, the stock's price may be significantly high — thereby pushing the P/B ratio to more than one — in the likely case that it has become a takeover target, a good enough reason to own the stock. Moreover, the P/B ratio is not without limitations. It is useful for businesses like finance, investments, insurance and banking or manufacturing companies with many liquid/tangible assets on the books. However, it can be misleading for firms with significant R&D expenditure, high debt, service companies, or those with negative earnings. In any case, the ratio is not particularly relevant as a standalone number. One should analyze other ratios like P/E, P/S and debt to equity before arriving at a reasonable investment decision. Here are five of the 19 stocks that qualified the screening: StoneCo provides financial technology solutions. The company offers an end-to-end cloud-based technology platform to conduct electronic commerce across in-store, online and mobile channels. StoneCo is based in Sao Paulo, Brazil. STNE has a Zacks Rank #1 and a Value Score of B. STNE has a projected 3-5-year EPS growth rate of 25.3%. You can see the complete list of today's Zacks #1 Rank stocks here. Headquartered in Woonsocket, RI, CVS Health (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. CVS Health presently has a Zacks Rank #2 and a Value Score of A. The company has a projected 3-5-year EPS growth rate of 11.4%. Headquartered in Sungnam, South Korea, KT Corporation provides telecommunication services. Its services include mobile telecommunications services, telephone services, fixed-line and VoIP telephone services. It also provides interconnection services to other telecommunications companies, broadband Internet access services and other Internet-related services. It also offers information technology and network services. KT has a Zacks Rank #2 and a Value Score of A. KT Corporation has a projected 3-5-year EPS growth rate of 50.4%. KB Financial Group is a commercial bank in Korea. The company provides credit and related financial services mainly to individuals and small and medium-sized enterprises. It also provides a range of deposit products and related services to individuals and enterprises of all sizes. KB Financial Group has a projected 3-5-year EPS growth rate of 11.9%. KB currently has a Zacks Rank #2 and a Value Score of A. USANA Health Sciences develops and manufactures high-quality nutritional, personal care and weight management products. USANA Health Sciences currently has a Zacks Rank #2 and a Value Score of A. USNA has a projected 3-5-year EPS growth rate of 12.0%. Get the remaining stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back-testing software. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit at: Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report KT Corporation (KT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report KB Financial Group Inc (KB) : Free Stock Analysis Report USANA Health Sciences, Inc. (USNA) : Free Stock Analysis Report StoneCo Ltd. (STNE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-08-2025
- Business
- Yahoo
StoneCo Ltd (STNE) Announced Divestment of its Software Segment
StoneCo Ltd. (NASDAQ:STNE) is one of the . On July 22, StoneCo Ltd. (NASDAQ:STNE) announced its divestment plan through which it will sell most of its software segment, including Linx and other related assets, to TOTVS for R$3.41 billion. The assets included in the announcement account for almost 79% of the segment's 2024 revenue. While this deal is subject to regulatory approvals, the company has completed the sale of its veterinary software SimplesVet to PetLove for R$140 million. After the sales of these assets, the company will retain a few software businesses which it plans to sell in the future. Management noted that this is a strategic move to focus more on its core business. The company noted that the utilization plan for the proceeds would be announced after the deals close. A team of software engineers in a digital workspace collaborating on a financial technology software solution. StoneCo Ltd. (NASDAQ:STNE) is a financial technology company that provides cloud-based payment and software solutions. While we acknowledge the potential of STNE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
